Background
Several minimally invasive, easy-to-use cancer diagnostic methods using peripheral blood samples have recently been developed to ease the physical burden on patients and to reduce cost and time [
1‐
3]. Computer-aided systems for data mining, (e.g., using multivariate analysis) are now readily available and have shown promising results when applied to metabolic profiles for diagnostic and clinical use [
4‐
6]. Several applications using metabolome analysis based on machine learning to diagnose human cancer using peripheral blood or urine have recently been demonstrated [
7‐
12].
Among metabolites, amino acids are one of the most suitable candidates for focused metabolomics because they are either ingested or synthesized endogenously and play essential physiological roles both as basic metabolites and metabolic regulators. To measure amino acids, plasma free amino acids (PFAAs), which are abundant in the circulation and link all organ systems, are favorable targets because PFAA profiles are influenced by metabolic variations in specific organ systems induced by specific diseases [
13‐
18]. Furthermore, several investigators have reported changes in PFAA profiles in cancer patients, including lung cancer patients [
19‐
27]. However, several discrepancies exist between the results of these studies due to the limited size of the data set [
22].
High-throughput techniques using high-performance liquid chromatography (HPLC)– electrospray ionization (ESI)–mass spectrometry (MS) to measure amino acids with sufficient accuracy for clinical use have also recently been developed [
28‐
31].
By combining these technologies, we recently obtained preliminary data on the efficacy of a diagnostic index based on PFAA concentrations, known as the “AminoIndex technology”, which compresses multidimensional information from PFAA profiles into a single dimension and maximizes the differences between patients and controls. This technology was shown to be useful in the early detection of colorectal, breast, and lung cancers in approximately 150 samples from a single medical institute [
32,
33]. Furthermore, we also verified the efficacy and statistical robustness of this method using larger sample sizes from multiple medical institutes and developed discriminating functions to detect five types of cancer, including lung, gastric, colorectal, breast, and prostate cancer [
34,
35]. We also found that changes in PFAA profiles that were common to all types of cancer as well as those specific to individual cancers [
34] .These functions are used in the “AminoIndex® Cancer Screening” service in Japan.
Lung cancer has been the leading cause of cancer death since 1998, and in Japan, >60,000 patients have died from lung cancer since 2005 [
36]. Conventionally, chest X-rays and sputum cytology are used to screen for lung cancer in patients in Japan. However, neither chest X-rays nor sputum cytology are ideal or versatile enough to detect early lung cancer. Although chest X-rays are useful for detecting peripheral lung cancer, this method is not always suitable for early detection [
37]. In addition, this technique requires highly skilled technicians to achieve sufficient accuracy. Sputum cytology has been reported to be useful only for the detection of squamous cell carcinoma and is inadequate for detecting adenocarcinoma (which is the major histological type of lung cancer in Japan) or for detecting lung cancer in asymptomatic non-smokers [
37].
Compared to chest X-ray and sputum cytology, a PFAA-based diagnostic method would be easier to use because it involves a relatively simple plasma assay, imposes a lower physical burden on patients and does not require advanced technical skills. Moreover, this method can also detect lung cancer regardless of cancer stage and histological type, including small cell lung cancer [
32,
34,
35].
In this study, we aimed to verify the usefulness of PFAA profiling for lung cancer detection using samples that had never been used as a data set to derive discriminating functions. As a result, highly reproducible results were observed in both the PFAA profiles and the discriminating performance of previously obtained PFAA-based, multiplex discriminant functions, suggesting the robustness of PFAA profiling for the early detection of lung cancer.
Discussion
In the present study, we verified the usefulness of PFAA profiling for lung cancer detection using new independent samples that had never been used for previous analysis and a derivation of multivariate discriminating function(s) that could distinguish lung cancer patients from control subjects. The results were highly reproducible for the change in PFAA profiles in lung cancer patients and highly discriminatory for lung cancer patients, including those with early stage cancer. Therefore, the results strongly suggest that our method is robust enough for clinical use. Moreover, because our method is a relatively simple plasma assay and imposes minimal physical burden on subjects, our findings suggest that PFAA profiling has great potential for improving the early detection of lung cancer.
Among the three discriminating functions, several amino acids were used in more than one function. His and Orn were incorporated into all of the functions, and Ser, Gln, Ala, Val, Ile, and Trp were incorporated into two of the three functions (Table
3) [
32,
34,
35]. According to a comparison between the study and test data sets, plasma concentrations of Pro, Ile and Orn were higher in each data set, while the concentrations of Gln, His and Trp were lower (Figure
1 and Table
2). Among these amino acids, changes in the plasma concentrations of four amino acids (Pro, Ile, His, and Orn) were identical to the changes in amino acids in lung cancer patients in previous studies. Maeda et al. have reported that plasma concentrations of Ser, Pro, Gly, Ala, Met, Ile, Leu, Tyr, Phe, Orn, and Lys are increased and His is decreased in lung cancer patients [
32]. Miyagi et al. have also reported that the plasma concentrations of Ser, Pro, Gly, Ile, and Orn are increased, whereas Gln, Cit, His, and Trp are decreased in lung cancer patients [
34]. Therefore, the results strongly suggest the robustness of these three discriminating functions for the detection of lung cancer.
Moreover, Miyagi et al. have also reported that plasma levels of Gln, Trp, His, Pro, and Orn are commonly altered in cancer patients with five types of cancer (lung cancer, gastric cancer, colorectal cancer, breast cancer, and prostate cancer) [
34]. Therefore, the data also strongly suggest that the changes in plasma concentrations of Pro, His, and Orn are essentially associated with carcinogenesis and cancer progression regardless of the location of the tumor.
Although tumor markers have been used extensively to detect lung cancer and estimate clinical condition, the markers are not always useful due to low specificity and insufficient sensitivity. Therefore, combinatorial use of two or more independent tumor markers is necessary for clinical utility [
39]. Our results suggest that a PFAA-based diagnostic method would be a novel index to improve the insufficient clinical performance of the tumor markers. Combinatorial use of the tumor markers with Discriminant- 3 showed higher sensitivities than any of the tumor markers generally used for lung cancer patients. Additionally, only a low correlation was observed between the discriminating function scores and the tumor marker levels, suggesting the independence of the PFAA profiles from the existing tumor markers. Miyagi et al. have suggested that the change in the PFAA profile in cancer patients reflects two aspects: metabolic changes common to many cancers and metabolic characteristics specific to each cancer [
34]. Indeed, although the results were preliminary, the same study demonstrated the possibility of discriminating the cancer type. To clarify this hypothesis, testing the behavior of the discriminating function scores in lung cancer patients after surgery and chemotherapy and in those with recurrence would be necessary.
Because this study was designed as a case–control study, the results cannot be directly applied to further observation or prediction. Therefore, additional validation using a larger sample size is necessary to establish the clinical utility of our approach. Nonetheless, we believe that our results strongly suggest the clinical usefulness of the PFAA-based diagnostic method for the detection of lung cancer.
Acknowledgements
We thank Dr. Hiroshi Miyano, Mr. Takashi Yamamoto, and Ms. Naoko Kageyama for the amino acid analysis, Dr. Katsuhisa Horimoto for help with the statistical analysis, and Ms. Mariko Takasu and Ms. Tomoko Kasakura for help with data acquisition. We also thank all members of the medical staff of the Chiba Cancer Center, the Osaka Medical Center for Cancer and Cardiovascular Diseases, the Gunma Prefectural Cancer Center, the Center for Multiphasic Health Testing and Services of the Mitsui Memorial Hospital, the Kameda Medical Center Makuhari, and the Kanagawa Health Service Association for help with sample collection.
Competing interest
Takashi Daimon, Osamu Tochikubo, and Minoru Yamakado have been consultants for Ajinomoto, Co., Inc. and receive consultancy fees from Ajinomoto, CO., Inc. Akira Imaizumi and Hiroshi Yamamoto are employees of Ajinomoto, CO., Inc. Masato Shingyoji, Toshihiko Iizasa, Masahiko Higashiyama, Fumio Imamura, Nobuhiro Saruki, Osamu Tochikubo, Toru Mitsushima, Minoru Yamakado, and Hideki Kimura have received research grants from Ajinomoto, CO., Inc. Masahiko Higashiyama, Fumio Imamura, Akira Imaizumi, and Hiroshi Yamamoto have applied for patents for plasma amino acid profiling using multivariate analysis as a diagnostic tool for lung cancer (WO2008/016111).
Authors’ contributions
AI, HY and HK designed this study. MS, TI, MH, FI, NS, and HK coordinated the study and collected the background data on the patients. HY, OT, TM, and MY also coordinated the study and supervised the collection of control subjects. MS and AI provided data analysis and wrote the manuscript. AI and TD performed statistical analyses. All authors read and approved the final paper.